

Chi-Tai Kuo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1427504/publications.pdf>

Version: 2024-02-01

64
papers

1,909
citations

304368

22
h-index

276539

41
g-index

66
all docs

66
docs citations

66
times ranked

3074
citing authors

#	ARTICLE	IF	CITATIONS
1	Oral Anticoagulant Use for Patients with Atrial Fibrillation with Concomitant Anemia and/or Thrombocytopenia. <i>American Journal of Medicine</i> , 2022, 135, e248-e256.	0.6	5
2	The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	16
3	Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 975-986.	1.3	20
4	Oral Anticoagulants and Antiplatelet Agents in Patients With Atrial Fibrillation and Concomitant Critical Limb Ischemia: A Nationwide Cohort Study. <i>Canadian Journal of Cardiology</i> , 2021, 37, 113-121.	0.8	3
5	Efficacy and Safety of Ticagrelor vs. Clopidogrel in East Asian Patients with Acute Myocardial Infarction: A Nationwide Cohort Study. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 443-451.	2.3	6
6	Non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation patients with concomitant peripheral artery disease. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 50-58.	1.4	18
7	Clinical Outcomes in Atrial Fibrillation Patients With a History of Cancer Treated With Non-Vitamin K Antagonist Oral Anticoagulants. <i>Stroke</i> , 2021, 52, 3132-3141.	1.0	20
8	Outcomes after ticagrelor versus clopidogrel treatment in end-stage renal disease patients with acute myocardial infarction: a nationwide cohort study. <i>Scientific Reports</i> , 2021, 11, 20826.	1.6	4
9	Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor. <i>Cardiovascular Diabetology</i> , 2020, 19, 160.	2.7	20
10	Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation. <i>Heart Rhythm</i> , 2020, 17, 2102-2110.	0.3	62
11	Impact of bleeding during dual antiplatelet therapy in patients with coronary artery disease. <i>Scientific Reports</i> , 2020, 10, 21345.	1.6	3
12	Aldehyde Dehydrogenase 2 Ameliorates Chronic Alcohol Consumption-Induced Atrial Fibrillation through Detoxification of 4-HNE. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6678.	1.8	19
13	Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants. <i>Cardiovascular Diabetology</i> , 2020, 19, 63.	2.7	26
14	Glycemic status and risks of thromboembolism and major bleeding in patients with atrial fibrillation. <i>Cardiovascular Diabetology</i> , 2020, 19, 30.	2.7	16
15	Direct Oral Anticoagulants in Atrial Fibrillation Patients With Concomitant Hyperthyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2893-2904.	1.8	7
16	Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or ROKET AF Trials) in Asian Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2019, 8, e013053.	1.6	19
17	Atrial fibrillation and its arrhythmogenesis associated with insulin resistance. <i>Cardiovascular Diabetology</i> , 2019, 18, 125.	2.7	73
18	Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation. <i>Chest</i> , 2019, 156, 529-543.	0.4	94

#	ARTICLE	IF	CITATIONS
19	Familial aggregation of myocardial infarction and coaggregation of myocardial infarction and autoimmune disease: a nationwide population-based cross-sectional study in Taiwan. <i>BMJ Open</i> , 2019, 9, e023614.	0.8	4
20	Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2019, 8, e011112.	1.6	54
21	A Novel DES L115F Mutation Identified by Whole Exome Sequencing is Associated with Inherited Cardiac Conduction Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6227.	1.8	4
22	Real-world Comparisons of Direct Oral Anticoagulants for Stroke Prevention in Asian Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 701-710.	1.3	24
23	Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	113
24	The effectiveness and safety of low-dose rivaroxaban in Asians with non-valvular atrial fibrillation. <i>International Journal of Cardiology</i> , 2018, 261, 78-83.	0.8	31
25	The CHA2DS2-VASc Score Predicts Major Bleeding in Non-Valvular Atrial Fibrillation Patients Who Take Oral Anticoagulants. <i>Journal of Clinical Medicine</i> , 2018, 7, 338.	1.0	14
26	End-stage renal disease patients using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may reduce the risk of mortality: a Taiwanese Nationwide cohort study. <i>Internal Medicine Journal</i> , 2018, 48, 1123-1132.	0.5	4
27	Cerebral desaturation in heart failure: Potential prognostic value and physiologic basis. <i>PLoS ONE</i> , 2018, 13, e0196299.	1.1	11
28	The risk of acute kidney injury in Asians treated with apixaban, rivaroxaban, dabigatran, or warfarin for non-valvular atrial fibrillation: A nationwide cohort study in Taiwan. <i>International Journal of Cardiology</i> , 2018, 265, 83-89.	0.8	34
29	Ratio of transmitral early filling velocity to early diastolic strain rate predicts outcomes in patients with systolic heart failure. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 79-85.	0.5	26
30	Left bundle-branch block contraction patterns identified from radial-strain analysis predicts outcomes following cardiac resynchronization therapy. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 869-877.	0.7	8
31	Association evidence of CCTTT repeat polymorphism in the iNOS promoter and the risk of atrial fibrillation in Taiwanese. <i>Scientific Reports</i> , 2017, 7, 42388.	1.6	3
32	Reply. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2471-2472.	1.2	1
33	Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1250.	3.8	292
34	Association of a Family History of Atrial Fibrillation With Incidence and Outcomes of Atrial Fibrillation. <i>JAMA Cardiology</i> , 2017, 2, 863.	3.0	28
35	Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan. <i>Cardiovascular Diabetology</i> , 2017, 16, 159.	2.7	44
36	MMP9 Rs3918242 Polymorphism Affects Tachycardia-Induced MMP9 Expression in Cultured Atrial-Derived Myocytes but Is Not a Risk Factor for Atrial Fibrillation among the Taiwanese. <i>International Journal of Molecular Sciences</i> , 2016, 17, 521.	1.8	6

#	ARTICLE	IF	CITATIONS
37	Protective role of heme oxygenase-1 in atrial remodeling. <i>Basic Research in Cardiology</i> , 2016, 111, 58.	2.5	27
38	Acute Kidney Injury in Asians With Atrial Fibrillation Treated With Dabigatran or Warfarin. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2272-2283.	1.2	64
39	Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1389-1401.	1.2	148
40	A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan. <i>Cardiovascular Diabetology</i> , 2016, 15, 56.	2.7	13
41	Proinflammatory gene expression in patients undergoing mitral valve surgery and maze ablation for atrial fibrillation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 151, 1673-1682.e5.	0.4	10
42	Cardiovascular, Bleeding, and Mortality Risks of Dabigatran in Asians With Nonvalvular Atrial Fibrillation. <i>Stroke</i> , 2016, 47, 441-449.	1.0	81
43	Comparison of Baseline versus Posttreatment Left Ventricular Ejection Fraction in Patients with Acute Decompensated Heart Failure for Predicting Cardiovascular Outcome: Implications from Single-Center Systolic Heart Failure Cohort. <i>PLoS ONE</i> , 2016, 11, e0145514.	1.1	8
44	Dialysis Patients with Implanted Drug-Eluting Stents Have Lower Major Cardiac Events and Mortality than Those with Implanted Bare-Metal Stents: A Taiwanese Nationwide Cohort Study. <i>PLoS ONE</i> , 2016, 11, e0146343.	1.1	10
45	Young Male Patients with Atrial Fibrillation and CHA ₂ DS ₂ -VASc Score of 1 May Not Need Anticoagulants: A Nationwide Population-Based Study. <i>PLoS ONE</i> , 2016, 11, e0151485.	1.1	17
46	Passive Leg Raising Correlates with Future Exercise Capacity after Coronary Revascularization. <i>PLoS ONE</i> , 2015, 10, e0137846.	1.1	3
47	Simvastatin+ezetimibe combination therapy is associated with a lower rate of major adverse cardiac events in type 2 diabetics than high potency statins alone: A population-based dynamic cohort study. <i>International Journal of Cardiology</i> , 2015, 190, 20-25.	0.8	22
48	Rosuvastatin suppresses atrial tachycardia-induced cellular remodeling via Akt/Nrf2/heme oxygenase-1 pathway. <i>Journal of Molecular and Cellular Cardiology</i> , 2015, 82, 84-92.	0.9	50
49	Microsatellite Polymorphism in the Heme Oxygenase-1 Gene Promoter and the Risk of Atrial Fibrillation in Taiwanese. <i>PLoS ONE</i> , 2014, 9, e108773.	1.1	8
50	Predictors of 1-year outcomes in the Taiwan Acute Coronary Syndrome Full Spectrum Registry. <i>Journal of the Formosan Medical Association</i> , 2014, 113, 794-802.	0.8	49
51	Comparison between Exclusive and Selective Drug-Eluting Stent Strategies in Treating Patients with Multivessel Coronary Artery Disease. <i>Acta Cardiologica Sinica</i> , 2014, 30, 181-9.	0.1	0
52	Region-specific gene expression profiles in the left atria of patients with valvular atrial fibrillation. <i>Heart Rhythm</i> , 2013, 10, 383-391.	0.3	57
53	Nicotinamide Adenine Dinucleotide Phosphate Oxidase 4 Mediates the Differential Responsiveness of Atrial Versus Ventricular Fibroblasts to Transforming Growth Factor- β ² . <i>Circulation: Arrhythmia and Electrophysiology</i> , 2013, 6, 790-798.	2.1	42
54	Whole-Exome Sequencing to Identify a Novel LMNA Gene Mutation Associated with Inherited Cardiac Conduction Disease. <i>PLoS ONE</i> , 2013, 8, e83322.	1.1	12

#	ARTICLE	IF	CITATIONS
55	C-Reactive Protein Gene Polymorphisms and the Risk of Atrial Fibrillation in a Chinese Population in Taiwan. <i>Acta Cardiologica Sinica</i> , 2013, 29, 208-16.	0.1	5
56	Clinical Assessment and Implication of Left Ventricular Mechanical Dyssynchrony in Patients with Heart Failure. <i>Acta Cardiologica Sinica</i> , 2013, 29, 505-14.	0.1	6
57	Transforming growth factor- β^2 and oxidative stress mediate tachycardia-induced cellular remodelling in cultured atrial-derived myocytes. <i>Cardiovascular Research</i> , 2011, 91, 62-70.	1.8	62
58	Propylthiouracil, independent of its antithyroid effect, produces endothelium-dependent vasodilatation through induction of nitric oxide bioactivity. <i>Atherosclerosis</i> , 2008, 196, 383-390.	0.4	12
59	Atrioventricular Nodal Reentry Tachycardia with Multiple AH Jumps: PACE - Pacing and Clinical Electrophysiology, 2003, 26, 1849-1855.	0.5	7
60	Atrial fibrillation: new horizons. <i>Chang Gung Medical Journal</i> , 2003, 26, 712-21.	0.7	1
61	Screw-in Atrial Lead in a Sick Sinus Syndrome Patient with Anomalous Inferior Vena Cava.. <i>International Heart Journal</i> , 2001, 42, 639-644.	0.6	4
62	Superior Vena Cava Syndrome as a Complication of Transvenous Permanent Pacemaker Implantation.. <i>International Heart Journal</i> , 1999, 40, 477-480.	0.6	13
63	Anticholinergic Overdose Induced Torsade de Pointes Successfully Treated with Verapamil.. <i>International Heart Journal</i> , 1996, 37, 925-931.	0.6	18
64	The G1691A mutation of the coagulation factor V gene (factor V Leiden) is rare in Chinese: an analysis of 618 individuals. <i>Human Genetics</i> , 1996, 98, 176-177.	1.8	28